专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210030868A1 FORMULATION OF ANTIBODY BASED DRUGS FOR TREATING LUNG CANCER BY INHALATION 有权
公开(公告)号：US20210030868A1
公开(公告)日：2021-02-04
申请号：US16942339
申请日：2020-07-29
申请人： Cai Gu Huang , Hai Long Zhang , Ning He
发明人： Cai Gu Huang , Hai Long Zhang , Ning He
IPC分类号： A61K39/395 , A61K9/00 , A61K47/22 , A61K47/26 , A61K47/12
摘要： The present invention relates to formulations and method of drug administration useful for treating lung cancer (in particular, non-small lung cancer) by administering a therapeutic antibody drug with a soft mist inhaler or by nebulization.

2. 发明申请

US20210393663A1 PHARMACEUTICAL FORMULATION CONTAINING ACTIVE METABOLITES OF REMDESIVIR OR ITS ANALOG FOR INHALATION 有权
公开(公告)号：US20210393663A1
公开(公告)日：2021-12-23
申请号：US17354702
申请日：2021-06-22
申请人： Cai Gu Huang , Ning He
发明人： Cai Gu Huang , Ning He
IPC分类号： A61K31/7064 , A61K9/08 , A61K47/40 , A61K47/18 , A61K47/02 , A61K9/00
摘要： The present invention relates to a liquid pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: (a) an active substance selected from the group consisting of alanine metabolite, nucleoside monophosphate, nucleoside triphosphate, and GS-441524; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer.

3. 发明申请

US20210205223A1 PROPELLANT-FREE FORMULATION FOR INHALATION 有权
公开(公告)号：US20210205223A1
公开(公告)日：2021-07-08
申请号：US17137559
申请日：2020-12-30
申请人： Cai Gu Huang , Ning He , Peng Peng Gu
发明人： Cai Gu Huang , Ning He , Peng Peng Gu
IPC分类号： A61K9/16 , A61K31/165 , A61K31/40
摘要： The present invention provides a propellant-free pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation in an inhaler. The propellant-free pharmaceutical formulation comprises: (a) glycopyrronium or a salt thereof; (b) formoterol or a salt thereof; (c) a pharmacologically acceptable stabilizer; (d) a pharmacologically acceptable preservative; and (d) a solvent. Additionally, the present invention provides the use of a combination product comprising glycopyrronium or a salt thereof and formoterol or a salt thereof for the prevention or treatment of chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

4. 发明申请

US20210220367A1 INHALABLE FORMULATION OF A SOLUTION CONTAINING GLYCOPYRROLATE AND OLODATEROL HYDROCHLORIDE 有权
公开(公告)号：US20210220367A1
公开(公告)日：2021-07-22
申请号：US17152049
申请日：2021-01-19
申请人： Cai Gu Huang , Xiao Qian Wang , Ning He
发明人： Cai Gu Huang , Xiao Qian Wang , Ning He
IPC分类号： A61K31/538 , A61K31/40 , A61K47/12 , A61K47/18 , A61K9/00 , A61K47/02
摘要： The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) glycopyrrolate or a salt thereof (b) olodaterol or a salt thereof; (b) a solvent; (c) a pharmacologically acceptable preservative, and (d) a pharmacologically acceptable stabilizer, and optionally other pharmacologically acceptable additives.

5. 发明申请

US20210378955A1 PHARMACEUTICAL FORMULATION CONTAINING UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE 有权
公开(公告)号：US20210378955A1
公开(公告)日：2021-12-09
申请号：US17342781
申请日：2021-06-09
申请人： Cai Gu Huang , Ning He
发明人： Cai Gu Huang , Ning He
IPC分类号： A61K9/08 , A61K31/439 , A61K31/138 , A61K47/40 , A61K47/26 , A61K47/02 , A61K47/18 , A61K47/12 , A61K9/12 , A61K9/00
摘要： The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) active substances selected from umeclidinium bromide and vilanterol trifenatate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer; and optionally includes other pharmacologically acceptable additives.

6. 发明申请

US20210346288A1 PHARMACEUTICAL FORMULATION CONTAINING ACTIVE METABOLITES OF REMDESIVIR FOR INHALATION 有权
公开(公告)号：US20210346288A1
公开(公告)日：2021-11-11
申请号：US17316933
申请日：2021-05-11
申请人： Cai Gu Huang , Ning He
发明人： Cai Gu Huang , Ning He
IPC分类号： A61K9/00 , A61K31/706 , A61K9/08 , A61K47/02 , A61K47/12 , A61K47/18 , A61K47/40
摘要： The present invention relates to pharmaceutical formulations containing one or more active metabolites of remdesivir selected from alanine metabolite (Ala-met), nucleoside monophosphate, remdesivir monophosphate disodium salt and nucleoside triphosphate (NTP) or their pharmaceutically acceptable salts or solvates that are suitable for administration by soft mist inhalation or nebulization inhalation.

7. 发明申请

US20210252027A1 PHARMACEUTICAL FORMULATION CONTAINING REMDESIVIR 有权
公开(公告)号：US20210252027A1
公开(公告)日：2021-08-19
申请号：US17168262
申请日：2021-02-05
申请人： Cai Gu Huang , Ning He
发明人： Cai Gu Huang , Ning He
IPC分类号： A61K31/675 , A61K47/40 , A61K47/18 , A61K9/00
摘要： The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulization or soft mist inhalation. The pharmaceutical formulation comprises: (a) remdesivir or a pharmaceutically acceptable salt thereof; (b) an excipient selected from the group consisting of (i) a pharmacologically acceptable stabilizer or complexing agent and (ii) a solubility enhancing agent; and (c) a solvent wherein the pharmaceutical formulation has a pH of between about 2.0 and about 6.0.

8. 发明申请

US20130077657A1 FINGER PLACEMENT IN MULTI-STAGE INTERFERENCE CANCELLATION 有权
标题翻译：多级干扰消除中的指示位置
公开(公告)号：US20130077657A1
公开(公告)日：2013-03-28
申请号：US13333703
申请日：2011-12-21
申请人： Yi-Pin Eric WANG , Stephen Grant , Ning He , Niklas Johansson
发明人： Yi-Pin Eric WANG , Stephen Grant , Ning He , Niklas Johansson
IPC分类号： H04B1/7115
CPC分类号： H04B1/7107 , H04B1/7115 , H04B2201/709727 , H04B2201/709745
摘要： In a receive node of a wireless network, an iterative multi-user multi-stage interference cancellation receiver is used. After each stage of interference cancellation, interference characteristics change. An adaptive finger placement strategy is used in which after each stage of interference cancellation, finger delays and combining weights of the receiver are adapted to reflect the changed interference characteristics.
摘要翻译：在无线网络的接收节点中，使用迭代多用户多级干扰消除接收机。在干扰消除的每个阶段之后，干扰特性发生变化。使用自适应手指放置策略，其中在干扰消除的每个阶段之后，接收机的手指延迟和组合权重适于反映改变的干扰特性。

9. 发明申请

US20120188951A1 Preferential Allocation of Different Length Scrambling Codes 有权
标题翻译：优先分配不同长度的加扰码
公开(公告)号：US20120188951A1
公开(公告)日：2012-07-26
申请号：US13163270
申请日：2011-06-17
申请人： Ning He , Stephen J. Grant , Andres Reial
发明人： Ning He , Stephen J. Grant , Andres Reial
IPC分类号： H04W72/04
CPC分类号： H04L25/03866 , H04L27/2655 , H04W72/0466 , H04W72/048 , H04W88/12
摘要： A base station herein assists a radio network controller (RNC) to allocate scrambling codes in a cell. The base station's assistance advantageously permits the RNC to allocate different length scrambling codes to different mobile terminals (or downlink carriers) in the cell. Specifically, the base station determines a preference for whether the length of a scrambling code to be allocated to each terminal or carrier should be short or long, based on whether uplink communications transmitted by the terminal, or downlink communications transmitted over the carrier, are to be processed with a high-complexity receiver or a low-complexity receiver. The RNC receives these preferences from the base station and takes them into account in order to allocate either a short scrambling code or a long scrambling code to each terminal or downlink carrier in the cell. The RNC then propagates the scrambling code allocations throughout the cell.
摘要翻译：这里的基站协助无线电网络控制器（RNC）在小区中分配扰码。基站的帮助有利地允许RNC向小区中的不同移动终端（或下行链路载波）分配不同长度的扰码。具体地，基于由终端发送的上行链路通信或者通过载波发送的下行链路通信，基站是否确定要分配给每个终端或载波的扰码的长度是短还是长用高复杂度接收机或低复杂度接收机进行处理。 RNC从基站接收这些偏好，并将其考虑在内，以便为小区中的每个终端或下行链路载波分配短扰码或长加扰码。 RNC然后在整个小区中传播扰码分配。

10. 发明授权

US07130263B1 Heterogeneous connections on a bi-directional line switched ring 有权
标题翻译：双向线路交换环上的异构连接
公开(公告)号：US07130263B1
公开(公告)日：2006-10-31
申请号：US09821981
申请日：2001-03-31
申请人： Lawrence Ong , James C. Pang , Ning He
发明人： Lawrence Ong , James C. Pang , Ning He
IPC分类号： G01R31/08
CPC分类号： H04J3/085
摘要： In one embodiment, a network element is to be coupled to a first and second span of a number of spans that interconnect a set of network elements to form a ring network. In addition, each of the spans has two sub-spans on which traffic travels in opposite directions on a number of channels that circumvent the ring. Additionally, the channels on each sub-span include working channels and protecting channels. Furthermore, the network element includes a traffic handler to reprogram, responsive to protection switches and un-switches, the connection configuration on the protecting channels of the sub-spans of the first and second spans that provide traffic to the network element.
摘要翻译：在一个实施例中，网络元件将被耦合到多个跨度的第一和第二跨度，其互连一组网络元件以形成环网络。此外，每个跨度具有两个子跨度，在跨越环绕环的多个通道上，交通在相反方向上行进。此外，每个子跨度的信道包括工作信道和保护信道。此外，网络元件包括响应于保护交换机和非交换机重新编程的交通处理器，在向网络元件提供业务的第一和第二跨度的子跨度的保护信道上的连接配置。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式